Abstract
<jats:p>The development of biological therapies in dermatology represents a significant milestone, driven by advances in understanding the pathophysiology of inflammatory skin diseases and the discovery of new therapeutic pathways. Biological therapies are molecules that specifically target cytokines involved in immune-mediated diseases. These treatments have been successfully utilized in dermatology for managing inflammatory dermatoses, particularly psoriasis, urticaria, autoimmune bullous diseases, and atopic dermatitis. However, due to the frequent underrepresentation of elderly patients in clinical trials, clinical and therapeutic data for this population remain relatively limited. The physiological changes associated with aging, along with comorbidities and polypharmacy, complicate treatment management in elderly patients. Traditional systemic anti-inflammatory agents, such as systemic corticosteroids, methotrexate, and cyclosporine, are often avoided in older adults due to the increased risk of toxicity and adverse effects. In contrast, biological agents, with their more favorable efficacy and safety profiles, may represent a more suitable therapeutic option for elderly patients.</jats:p>